Ocular Therapeutix (OCUL): Officer filed to sell ~$70K
PETER KAZUO KAISER, Officer at Ocular Therapeutix, filed to sell ~$70K of Ocular Therapeutix shares.
- ~$70K
- planned to sell · 9,990 shares, around Oct 2, 2026
- Planned for
- Oct 2, 2026
- Notice filed
- Oct 2, 2026
What stands out in this filing
- The planned sale is less than 0.01% of the company's shares outstanding.
- How the shares were acquired, per the notice: Restricted Stock Vesting Under a Registered Plan.
- The notice says the shares were received as pay (stock awards or options).
- Broker named on the notice: Morgan Stanley Smith Barney LLC Executive Financial Services.
- A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 3, 2026Company filing · Form 8-K · ResultsReported its results
- Oct 2, 2026Insider · 2 peopleInsiders: 2 sales (~$147K)
What came next
- Oct 8, 2026InsiderOfficer sold ~$87K of OCUL shares in the open market
- Oct 14, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.”
- Nov 5, 2026InsiderOfficer sold ~$232K of OCUL shares in the open market
- Nov 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 6, 2026, the Board of Directors (the “Board”) of Ocular Therapeutix, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Riad Sherif, M.D., to serve as a member of the Board, effective immediately.”
- Nov 9, 2026Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 144
Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.
Full guide: What is an SEC Form 144?
What else is on file for Ocular Therapeutix
For Ocular Therapeutix, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OCUL page.
How this filing works
Explore the data
Common questions
Which Ocular Therapeutix (OCUL) insider traded, and how much?
PETER KAZUO KAISER, Officer at Ocular Therapeutix, filed to sell ~$70K of Ocular Therapeutix shares. 9,990 shares, Form 144 notice of a planned sale.
When did it happen, and when was it made public?
Planned for: Oct 2, 2026. Notice filed: Oct 2, 2026.
What stands out in this filing?
The planned sale is less than 0.01% of the company's shares outstanding. How the shares were acquired, per the notice: Restricted Stock Vesting Under a Registered Plan. The notice says the shares were received as pay (stock awards or options).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Ocular Therapeutix recently?
For Ocular Therapeutix, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the OCUL page.
Does this mean OCUL stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Ocular Therapeutix
- SEC Form 4Nov 9, 2026
- SEC Form 144Nov 5, 2026
- SEC Form 4Oct 13, 2026
- SEC Form 144Oct 8, 2026
- SEC Form 4Oct 7, 2026
- SEC Form 4Oct 7, 2026
Everything OQRO holds on this company is on its OCUL page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data